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The  aim  of  the  presented  investigation  was  to document  challenges  encountered  during  implementation
and  qualiﬁcation  of  a  method  for  bisphenol  A (BPA)  analysis  and  to develop  and  discuss  precautions
taken  to avoid  and to monitor  contamination  with  BPA  during  sample  handling  and  analysis.  Previously
developed  and  published  HPLC–MS/MS  methods  for the  determination  of  unconjugated  BPA  (Markham
et  al.  Journal  of Analytical  Toxicology,  34  (2010)  293–303)  [17]  and  total  BPA  (Markham  et  al. Journal
of  Analytical  Toxicology,  38 (2014)  194–203)  [20]  in  human  urine  were  combined  and  transferred  into
another  laboratory.  The  initial  method  for unconjugated  BPA  was developed  and  evaluated  in two  inde-
pendent  laboratories  simultaneously.  The  second  method  for total  BPA  was  developed  and  evaluated  in
one of  these  laboratories  to  conserve  resources.  Accurate  analysis  of  BPA  at sub-ppb  levels  is a  challeng-
ing  task  as  BPA  is  a widely  used  material  and  is  ubiquitous  in the  environment  at trace  concentrations.
Propensity  for  contamination  of  biological  samples  with  BPA  is  reported  in the literature  during  sam-
ple  collection,  storage,  and/or  analysis.  Contamination  by trace  levels  of  BPA  is so  pervasive  that  even
with  extraordinary  care,  it is difﬁcult  to  completely  exclude  the introduction  of BPA  into  biological  sam-
ples and,  consequently,  contamination  might  have  an impact  on  BPA  biomonitoring  data.  The  applied
UPLC–MS/MS  method  was  calibrated  from  0.05 to  25  ng/ml.  The  limit  of quantiﬁcation  was  0.1  ng/ml
for  unconjugated  BPA  and  0.2  ng/ml  for total  BPA,  respectively,  in human  urine.  Finally,  the  method  was
applied  to urine  samples  derived  from  20 volunteers.  Overall,  BPA  can  be  analyzed  in human  urine  with
acceptable  recovery  and  repeatability  if  sufﬁcient  measures  are  taken  to  avoid  contamination  throughout
le  co
ublisthe  procedure  from  samp
© 2015  The  Authors.  P
. IntroductionBisphenol A (BPA1) is a high production volume compound. It is
ainly used as a monomer to make polymers for various applica-
∗ Corresponding author at: Bayer Pharma Aktiengesellschaft, Wuppertal,
ermany. Fax: +49 202 368839.
E-mail address: dieter.beyer@bayer.com (D. Beyer).
1 Abbreviations: BPA: the unmetabolized, bioactive parent form also called in the
iterature “free” or aglycone. Total BPA: the sum of all BPA from unconjugated BPA
ttp://dx.doi.org/10.1016/j.jchromb.2015.09.020
570-0232/© 2015 The Authors. Published by Elsevier B.V. This is an open access article ullection  until  UPLC–MS/MS  analysis.
hed  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
tions including food-contact applications. Human exposure to BPA
is investigated in a number of biomonitoring studies and shown to
be low and mainly due to BPA that migrates into food from polymers
[1,2,13].
Some studies report measurable concentrations of unconju-
gated BPA in urine and other biological ﬂuids and conclude
plus all conjugated metabolites. BPA-G: the conjugated metabolite BPA-glucuronide.
BPA-S: the conjugated metabolite BPA-sulfate.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ncomplete pre-systemic clearance [4–8]. Comprehensive toxi-
okinetic studies with labelled methyl-d6-BPA (d6-BPA) to avoid
onfounding with background contamination clearly conﬁrm that
irtually complete pre-systemic clearance of orally administered
PA occurs in humans by metabolism of unconjugated BPA to BPA-
lucuronide (BPA-G) [3,4,9–12], which is a biologically inactive
orm [13].
Based on the periodic exposure, quantitative elimination via
rine and the short half-life of 4–5 h, urine is considered to be
he appropriate specimen to assess exposure to BPA [3,13–19].
here are different analytical methods reported in the literature to
easure unconjugated and total BPA in urine. Because the sample
reparation and analytical methods in many of the biomonitor-
ng papers are poorly described, it usually cannot be ascertained
f the methods used are fully validated. Important parameters are
requently not reported, such as, if there was appropriate use of
olvent standards, blanks, matrix controls, and fortiﬁed matrix con-
rols to assure data quality, or if specimen collection and storage
evices were screened to conﬁrm the absence of BPA. Contam-
nation by trace levels of BPA is so pervasive that even with
xtraordinary care, it is difﬁcult to completely exclude the intro-
uction of BPA into biological samples [13,17–20].
Adequate generation of biomonitoring data requires validated
nd high-quality analytical methods, qualiﬁed laboratory per-
onnel, and strict quality control/quality assurance laboratory
ractices [1]. The use of GC–MS and LC–MS/MS methods for analy-
is enhanced sensitivity and selectivity and facilitated replacement
f less-speciﬁc methods such as enzyme linked immunosorbent
ssays (ELISA), which suffer from cross-reactivity with the major
PA metabolite, BPA-glucuronide [3,21].
This publication describes the transfer of an LC–MS/MS method
reviously developed to measure unconjugated and total BPA in
rine [17,20] to another laboratory. The study indicates pitfalls
ncountered during method implementation and qualiﬁcation and
iscusses troubleshooting and precautions taken to avoid and to
onitor contamination with BPA during sample handling and anal-
sis.
. Materials and methods
.1. Chemicals and materials
12C BPA (purity 99.7%), citric acid, tert-butyl methylether
t-BME) and -glucuronidase (type HP-2, product number:
7017; >100,000 units/ml; with a secondary activity of sulfatase
7500 units/ml) were purchased from Sigma–Aldrich (Saint Louis,
O,  USA). An authentic standard of BPA-mono-ß-(d)-glucuronide
odium salt (BPA-G sodium salt), (90.1 %) was obtained from
FC Ltd., Manchester, England. An authentic standard of 13C12-
PA-G, Lot TA0627 V, 95.6% chemical purity, 100% isotopic purity
as obtained from Sigma–Aldrich, Inc., Isotec Inc., Miamisburg,
H. 13C12-BPA (100 g/ml solution, 99%) and the internal stan-
ard 12C BPA-d8 (chemical purity 100%; isotopic enrichment 98%)
ere obtained from Cambridge Isotope Laboratories Inc. (Andover,
A,  USA). Sodium hydroxide and ammonia solution (25%) were
rom Merck (Darmstadt, Germany). Methanol, ammonium acetate,
cetonitrile and dichloromethane were purchased from Biosolve
Valkenswaard, The Netherlands). The water used was obtained
rom a Millipore water puriﬁcation system (Merck Millipore,
armstadt, Germany). All chemicals used were of best quality.
olid phase extraction (SPE) cartridges (Oasis HLB 200 mg/5 ml;
P glass) were obtained from waters chromatography BV (Etten-
eur, The Netherlands). Glass amber autosampler vials (Grace) and
aps (blue PP screw top, red PTFE/white silicone; Grace) were
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2.2. Precautions
Glassware was used whenever possible and cleaned with
dichloromethane to eliminate any potential background of BPA.
13C12-BPA served as the “surrogate” analyte for 12C BPA to aid
in problem solving in case of 12C BPA background contamination.
For the same reason, 13C12-BPA-G served as the “surrogate” ana-
lyte for 12C BPA-G. To demonstrate that the UPLC system was not
contaminated with trace amounts of 12C BPA and to avoid false
positive responses in the UPLC–MS system, blank solvent (acetoni-
trile/water, 50/50) was analyzed at the start of each analytical run
and between the urine samples.
2.3. Preparation of reference standard stock solutions
The stock solutions of 12C BPA and the internal standard 12C BPA-
d8 were prepared by dissolving 10 mg  of the substance into 100 ml
acetonitrile. The stock solutions of the 12C BPA-G sodium salt and
13C12-BPA-G were prepared by dissolving 10 mg  of the substance
into 100 ml  acetonitrile/water (50/50, V/V). Preparation of 12C BPA
stock solutions was  performed in a separate room, different from
the analytical laboratories, to avoid contamination.
2.4. Calibration standards
The calibration standards were prepared by spiking ace-
tonitrile/water (50/50, V/V) with 12C BPA and 13C12-BPA at
concentration levels 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10, 20, and
25 ng/ml. A 100 l aliquot of the internal standard solution (1 g/ml
acetonitrile/water (50/50, V/V)) was added to the calibration stan-
dards (10 ml). After preparation, the calibration standards were
stored at 2–10 ◦C for up to several months.
2.5. Calibration procedure
Calibration standards were not processed through SPE columns
and analyzed at the start and end of each analytical run. All 20 cali-
bration results (10 levels, in duplicate) were used to construct one
calibration curve. Linear calibration curves were obtained by plot-
ting the quotient of the peak area of 12C BPA or 13C12-BPA divided
by the deuterated internal standard against the standard concen-
tration. The blank solvent with internal standard was not included
in the calibration curve. The 12C BPA concentration in the blank sol-
vent was  low (<0.02 ng/ml) and, consequently, not subtracted from
the 12C BPA signals obtained from the calibration standards.
2.6. Sample collection
Blank urine from volunteers (TNO Triskelion) was collected in
coded glass beakers without personal information. All volunteers
gave informed consent for their donations. All glassware used for
sample handling was pre-rinsed with dichloromethane to elim-
inate trace amounts of 12C BPA. The blank urine was stored at
≤−18 ◦C until analysis. Pooled urine was prepared by mixing urine
from several volunteers.
2.7. Sample preparation
The urine samples were pre-treated using the method described
by Markham et al. [17,20]. In short:
Determination of unconjugated BPA: 5 ml  urine was  transferred
into a 15 ml  glass tube, 10 l internal standard solution (1 g/ml)
was added and the sample was  intensively agitated. The SPE car-
tridge was  conditioned with 4 ml  t-BME, 3 ml  methanol and 5 ml
water, and the prepared urine sample was  loaded. The urine sam-
ple ran through the SPE cartridge without vacuum. Subsequently,
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Table 1
UPLC gradient for the analysis of BPA.
Time (min) Flow rate (ml/min) Mobile phase A (%) Mobile phase B (%)
0.0 0.3 90.0 10.0
0.5 0.3 90.0 10.0
5.0  0.3 35.0 65.0
6.0  0.3 35.0 65.0
6.1  0.3 5.0 95.0
T
M2 B. Buscher et al. / J. Chro
 ml  water was added to the SPE cartridge (without vacuum). The
artridge was washed with 3 ml  of 10% methanol/2% ammonium
ydroxide in water, dried with (medium) vacuum for 5 s, washed
ith 5 ml  of water, dried with (medium) vacuum for 5 s, washed
ith 3 ml  of 50% methanol in water, dried with (medium) vacuum
or 5 s, washed with 3 ml  of dichloromethane and dried with high
acuum for 60 s. The SPE cartridge was placed onto a 10 ml  glass
ube. BPA was eluted with 4 ml  t-BME at atmospheric pressure. The
xtract was evaporated to dryness under a gentle stream of nitro-
en at 40 ◦C in a water bath. The residue was dissolved in 1 ml  of
0% acetonitrile in water. The sample solution was transferred to
n autosampler vial.
Determination of total BPA: 5 ml  urine was transferred into a
5 ml  glass tube, 10 l internal standard solution (1 g/ml) was
dded and the sample was intensively agitated. 5 ml  of buffer solu-
ion (pH 4.5–5.0, prepared by dissolving 18.4 g citric acid and 6.5 g
odium hydroxide into 1000 ml  water in a glass bottle) was added
nd the sample was mixed. 50 l ß-glucuronidase (6086 units) was
dded. The sample was intensively agitated after which the sample
as incubated in a shaking water bath for 16 h at 37 ◦C. The SPE car-
ridge procedure was followed as described above for unconjugated
PA.
Recent comprehensive toxicokinetic studies with methyl-d6-
PA (d6-BPA) report total BPA concentrations in serum and urine
o be higher than the sum of BPA and BPA-G [10,11]. Thayer et al.
xposed adult humans to 100 g/kg bw d6-BPA by oral adminis-
ration and conducted blood and urine analysis over a three day
eriod. The authors used a Helix pomatia glucuronidase/sulfatase
ixture to generate total BPA and reported virtually quantita-
ive recovery of total administered d6-BPA in urine (84–109%). In
rine samples aggregated from all subjects d6-BPA-G represented
7 ± 6.9% of the total d6-BPA excreted and d6-BPA-S was  3 ± 2.3%.
he authors tentatively identiﬁed mixed sulfate/glucuronide bis-
onjugate in both urine and serum. The hydrolysis method used
n our study was optimized to hydrolyze BPA-G, the main BPA
etabolite, and utilized >5000 units/sample H. pomatia type-2 -
lucuronidase (HP-2) and incubation for 16 h at 37 ◦C [20]. Since
P-2 -glucuronidase expresses up to 7.5% secondary activity
f sulfatase (≤350 units/sample) it is assumed, but not experi-
entally veriﬁed, that BPA-S and any BPA bis-conjugates would
e hydrolyzed to BPA under the conditions used. For future
xperiments it should be considered to verify complete BPA-S and
is-conjugates hydrolysis with authentic standards.
.8. Method qualiﬁcation procedures
.8.1. Determination of unconjugated BPA in urine
For the determination of unconjugated BPA, pooled human urine
5 ml)  was spiked with 12C BPA and 13C12-BPA at six concentration
evels ranging from 0.1 to 5.0 ng/ml. Five individual samples of each
evel, including blank urine, were pre-treated (SPE) and individually
easured..8.2. Determination of total BPA in urine
For the determination of total BPA, pooled human urine
amples (5 ml)  were spiked with 12C BPA and 13C12-BPA (6 lev-
able 2
RM  conditions for 12C BPA, 13C12-BPA and BPA-d8.
Compound Parent (m/z) Daughter (m/z) 
12C-BPA 227.10 132.90 
12C-BPA 227.10 211.95 
BPA-d8 (IS) 235.15 136.90 
BPA-d8 (IS) 235.15 220.00 
13C12-BPA 239.10 138.95 
13C12-BPA 239.10 224.00 7.0  0.3 5.0 95.0
7.1  0.3 90.0 10.0
els; 0.2–10 ng/ml) to demonstrate appropriate recovery rates.
Each level, including blank urine, was individually pre-treated
(enzymatic treatment and SPE) and investigated in 5 indepen-
dent samples, and each sample was  analyzed individually with
UPLC–MS/MS.
In addition, pooled human urine samples (5 ml)  were spiked
with 12C BPA-G and 13C12-BPA-G (6 levels; 0.5–20 ng/ml) to deter-
mine quantitative BPA-G hydrolysis. Each level, including blank
urine, was individually pre-treated (enzymatic treatment and SPE)
and investigated in 5 independent samples, and each sample was
analyzed individually with UPLC–MS/MS.
2.9. Determination of unconjugated and total 12C BPA in
individual urine samples
The qualiﬁed methods were applied to urine samples from 20
volunteers. For the determination of unconjugated 12C BPA, urine
samples of the 20 individuals were processed (SPE) and analyzed
in three different replicate samples. In the same analysis run, cal-
ibration standards were analyzed as well as pre-treated water,
pooled urine and pooled urine spiked with 12C BPA and 13C12-BPA
(0.5 ng/ml).
For the determination of total 12C BPA, urine samples of the
20 individuals were processed (enzymatic treatment and SPE) and
analyzed in three different replicate samples. In the same analy-
sis run, calibration standards were analyzed as well as pre-treated
water, pooled urine and pooled urine spiked with 12C BPA-G and
13C12-BPA-G (1 ng/ml).
2.10. Ultra performance liquid chromatography–tandem mass
spectrometry
All samples were analyzed using an Acquity UPLC system
(Waters Corporation) connected to a XEVO-TQS mass spectrom-
eter (Waters). The analytical column was  Acquity UPLC®BEH C18,
(2.1 × 100 mm,  1.7 m).  The column temperature was 50 ◦C. A trap
column (XBridge C18; 2.5 m,  2.1 × 50 mm)  was installed between
the mixing chamber and the analytical column to separate BPA
contamination that may  originate from the UPLC system. The
temperature of the trap column was not controlled (room temper-
ature). The injection volume was  10 l. The mobile phases A and
B consisted of 1 mM ammonium acetate solution and acetonitrile,
respectively. Table 1 shows the UPLC gradient.
Electrospray ionization in the negative mode was performed
using multiple reaction monitoring (MRM). Table 2 shows the ions
Cone voltage (V) Collision energy (eV) Remark
48.0 22.0 Qualiﬁer
48.0 18.0 Quantiﬁer
48.0 24.0 Qualiﬁer
48.0 18.0 Quantiﬁer
48.0 26.0 Qualiﬁer
48.0 20.0 Quantiﬁer
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Table 3A
Precautions taken to avoid and to monitor contamination of 12C BPA during sample
handling and analysis.
No. Precautions
1 The milli-Q water used for all experiments (including mobile phase)
was extracted with dichloromethane to eliminate trace amounts of
BPA in the water.
2  All glass materials, including the collection ﬂasks for urine samples,
were pre-rinsed with dichloromethane.
3  A trap column was installed between the mixing chamber and the
analytical column to separate BPA, that may  originate from the UPLC
system (minor contamination), from the BPA in the samples.
4  UPLC gradient was slowed down (and the cone voltage for the internal
standard was adjusted).
5  Preparation of 12C BPA stock solutions and sample pre-treatment
combined with UPLC–MS/MS were performed in separate laboratories
to  avoid contamination.
6 Before and between the UPLC–MS analysis of urine samples multiple
blank solvent (acetonitrile/water, 50/50) injections were performed to
reassure that the UPLC system was BPA-free, and to avoid false
positives.
7  In each run, at least 3 blank water samples were pre-treated (SPE)
together with the urine samples to make sure that no BPA was
introduced during sample pre-treatment.
8  Unconjugated BPA and total-BPA should be measured for each sample
in  parallel; a substantial fraction of unconjugated BPA (e.g., >1%) is
sure that no C BPA was introduced during sample pre-treatment,
(3) blank solvent (acetonitrile/water, 50/50) was analyzed at the
start of each analysis run and between the urine sample extracts
to demonstrate that the UPLC system was not contaminated with
Table 3B
Pitfalls encountered during implementation and qualiﬁcation of the SPE-
UPLC–MS/MS methods.
Observation Precautions taken (see Table 3A)
All (non-pre-treated) blank solvents
(water, acetonitrile) contained 12C BPA
due to contamination of the
UPLC-system.
1, 2, 3, 5, 6
Blank water contained BPA after SPE;
blank water was  contaminated during
SPE procedure.
1, 2, 5, 7
Blank urine sample contained BPA
after SPE; blank urine sample was
contaminated during sample collection
or  during SPE procedure.
1, 2, 5, 7, 8
Large variation of recovery after SPE 4B. Buscher et al. / J. Chro
onitored for 12C BPA, 13C12-BPA and BPA-d8. The dwell time was
.060 s. Mass spectrometry data were collected (6.0 min), processed
nd evaluated using MassLynx software version 4.1 (Waters).
. Results and discussion
.1. Acceptance criteria
For the spiked urine samples, the acceptance criteria were set
t an accuracy of 80–120%, and a precision (CV) of 20%. To monitor
ontamination during sample preparation at least 3 blank water
amples were pre-treated and analyzed in each analytical run. The
cceptance criterion for the blank SPE processed water samples
as a BPA concentration <0.1 ng/ml. For the calibration curve, the
cceptance criterion was  a minimum of 75% of calibration standards
ithin ±15% relative error of the nominal concentration (±20% at
LOQ) and a coefﬁcient of determination better than 0.995.
.1.2. Analyte conﬁrmation
As outlined in Markham et al. [20] an additional criterion of
S–MS  transition ratio was added to these data to improve the
ethod speciﬁcity. This ratio is deﬁned as the average of the con-
rmation ion transition response divided by the quantitation ion
ransition response observed for the solvent standards analyzed
n a given sample set; 12C BPA (m/z 212 quantiﬁer and m/z 133
onﬁrmation), 12C BPA-d8 (m/z 220 quantiﬁer and m/z 137 conﬁr-
ation), 13C BPA (m/z 224 quantiﬁer and m/z  139 conﬁrmation).
he acceptance criteria for the sample transition ratio were ±20%
f the average standard transition ratio. A higher sample transi-
ion ratio indicates potential issues in the sample measured (e.g.,
uenching).
.2. Implementation of the method
The method for the analysis of BPA in human urine published
y Markham et al. [17,20] was implemented and slightly adjusted:
ltra performance liquid chromatography (UPLC, Acquity, Waters)
as used instead of HPLC, and a different triple quadrupole mass
pectrometer (XEVO-TQS, Waters) was used. During the early
mplementation of the method several pitfalls were encountered
Tables 3A and 3B):
Blank water, pre-treated with SPE, showed a 12C BPA signal
far above the acceptance limit of 0.1 ng/ml, whereas the 12C
BPA signal in non-pretreated water was below 0.1 ng/ml; it
was concluded that contamination occurred during sample pre-
treatment (SPE).
A high 12C BPA signal was observed in pooled blank urine; this
contamination was assumed to occur either during sample col-
lection or SPE work-up.
Non-pretreated blank solvents (water, acetonitrile) showed a
measurable 12C BPA signal. Contamination of the UPLC system
(mobile phase, injection vials) was suspected.
To avoid 12C BPA contamination from sample collection until
PLC–MS analysis several special measures were taken: all glass
aterials including glass beakers for collection of urine sam-
les were pre-rinsed with dichloromethane to eliminate trace
mounts of 12C BPA. For the same reason, water used for SPE
nd for the preparation of mobile phase and buffer was  extracted
ith dichloromethane before use. In addition, a trap column was
nstalled between the mixing chamber and the analytical column
o separate 12C BPA that may  originate from the UPLC system from
2C BPA in the samples.likely to indicate contamination of urine and/or hydrolysis during
sample preparation and/or measurement.
After the implementation of the unconjugated BPA method in
human urine another issue occurred: a large variability of the 12C
BPA and 13C12-BPA recovery rates from pooled urine samples was
observed after the SPE procedure including enzymatic hydrolysis
(total BPA method). Apparently, the internal standard (BPA-d8) did
not properly correct for recovery variations due to a matrix effect;
an endogenous compound in the pooled urine that eluted at the
same retention time as the internal standard may  have affected the
ionization of the internal standard. By adjusting the UPLC gradient
procedure, the matrix effect disappeared and the recovery of 12C
BPA and 13C12-BPA from pooled urine was  improved.
In addition to the above mentioned special measures more gen-
eral precautions were taken as well, i.e. (1) the preparation of the
12C BPA stock solution and sample pre-treatment combined with
UPLC–MS analysis were performed in separate laboratories to avoid
contamination, (2) in each analytical run at least three blank water
samples were pre-treated together with the urine samples to make
12including enzymatic treatment (total
BPA method); the BPA-d8 (IS) signal
did not compensate for matrix effect in
pooled urine samples.
34 B. Buscher et al. / J. Chromatogr. B 1005 (2015) 30–38
Table  4
Validation results of unconjugated BPA in pooled human urine. Pooled human urine was spiked with 12C-BPA and 13C12-BPA at six concentration levels. Each level was
pre-treated (SPE). The mean unconjugated 12C-BPA concentration in pooled blank urine was 0.043 ng/ml (CV: 20.0%; n = 5).
Spiked Mean CV Correcteda Accuracy Mean accuracy
12C-BPA n = 5 12C-BPA conc. (%) 12C-BPA conc. 12C-BPA (%) 12C-BPA (%)
(ng/ml)  (ng/ml) (ng/ml)
0.0 0.043 20.0 NA NA NA
0.10  0.14 9.1 0.094 85–115 94
0.20  0.24 2.1 0.20 99–104 101
0.50  0.53 3.5 0.48 92–102 97
1.0 1.0 2.4 0.96 93–100 96
2.0 2.0  1.6 2.0 98–102 100
5.0  5.1 1.4 5.0 99–103 101
Spiked Mean CV Accuracy Mean accuracy
13C-BPA n = 5 13C-BPA conc. (%) 13C-BPA (%) 13C-BPA (%)
(ng/ml)  (ng/ml)
0 0 NA NA NA
0.1  0.09 1.8 89–92 90
0.2  0.19 1.9 91–95 93
0.5  0.48 2.7 91–98 95
1  0.95 2.2 91–96 95
2  2 1.9 97–102 100
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a The accuracy of 12C-BPA in spiked urine samples was calculated after subtractio
race amounts of 12C BPA and (4) only dichloromethane cleaned
lass materials were used for sample handling (plastic materials
ere avoided whenever possible).
.3. Calibration results
The optimized method was applied to the analysis of calibra-
ion standards. Calibration of 12C BPA and 13C12-BPA using linear
egression with weighting factor 1/x was successfully performed in
he range from 0.05 to 25 ng/ml. 13C12-BPA was added to the cal-
bration standards to compare the performance of the method for
he two compounds, and to aid in problem solving in case of 12C
PA contamination. The relative error (%) was within the accep-
ance criteria for 12C BPA and 13C12-BPA. Fig. 1A shows a mass
hromatogram of blank solvent (acetonitrile/water, 50/50) spiked
ith internal standard (BPA-d8) only (no 12C BPA and 13C12-BPA
ere added to the solvent). Despite all measures taken to avoid 12C
PA in blank solutions, a very small 12C BPA signal was  observed in
he blank solvent (at 4.97 min) whereas the 13C12-BPA signal was
ero. Fig. 1B shows a mass chromatogram of the lowest calibra-
ion standard (12C BPA and 13C12-BPA concentration: 0.05 ng/ml).
lthough for 13C12-BPA the signal-to-noise ratio was higher than
or 12C BPA, due to the 12C BPA background, both calibration curves
nabled reliable quantiﬁcation in the range from 0.05 to 25 ng/ml.
.4. Method qualiﬁcation results
.4.1. Determination of unconjugated BPA in urine
The method qualiﬁcation results of unconjugated BPA in pooled
uman urine are presented in Table 4. For each of the 6 validation
evels the mean measured 12C BPA and 13C12-BPA concentration
nd the coefﬁcient of variation (CV) were calculated. The 13C12-
PA signal in water and human urine was zero. For 13C12-BPA the
ccuracy was 90–100% with a maximum CV of 2.7%.
The mean unconjugated 12C BPA concentration in blank pooled
uman urine was 0.043 ng/ml (n = 5); this 12C BPA concentration
an be considered as background signal because the mean 12C BPA
n pre-treated water was 0.052 ng/ml (n = 5). The accuracy of 12C
PA in spiked urine samples was calculated after subtraction of
he mean 12C BPA signal in blank pooled urine. The accuracy of
piked 12C BPA in pooled human urine ranged from 94% to 101%
maximum CV of 9.1%). Based on these results it can be concluded99–102 100
he mean signal in pooled blank urine.
that the method enabled reliable quantiﬁcation of unconjugated
12C BPA and 13C12-BPA in human urine at a Limit of Quantiﬁcation
(LOQ) of 0.1 ng/ml.
3.4.2. Determination of total BPA in urine (spiked with BPA)
The results of the method qualiﬁcation are presented in Table 5.
The 13C12-BPA signal in water and human urine was zero. For 13C12-
BPA the accuracy varied from 89% to 101%, indicating that without
background signal the analytical method worked well.
The total 12C BPA concentration, i.e., unconjugated 12C BPA
plus 12C BPA originating from conjugated metabolites, in pooled
blank urine was  0.843 ng/ml (n = 5). This level was  above the back-
ground level of 12C BPA in pre-treated water (0.063 ng/ml; n = 5).
The accuracy of 12C BPA in spiked urine samples was calculated
after subtraction of the mean 12C BPA background signal in pooled
blank urine. The accuracy of spiked 12C BPA in pooled human urine
was between 78% and 102% with good reproducibility. These results
showed that even on top of the total 12C BPA in pooled “blank” urine
(0.843 ng/ml) the spiked level of 0.2 ng/ml can be measured accu-
rately. Therefore, the LOQ for total BPA in human urine was  set at
0.2 ng/ml.
3.4.3. Determination of total BPA in urine (spiked with BPA-G)
The total BPA concentration was determined in pooled human
urine which was  spiked with 12C BPA-G and 13C12-BPA-G. Dur-
ing sample pre-treatment 12C BPA-G and 13C12-BPA-G were
enzymatically converted to 12C BPA and 13C12-BPA, respectively.
13C12-BPA-G served as the “surrogate” analyte for 12C BPA-G to
compare the performance of the method for the two compounds,
taking into account that potential contamination with 12C BPA
might have an inﬂuence on the concentration and accuracy.
Fig. 2A shows the mass chromatogram of blank pooled human
urine spiked with internal standard: no 13C12-BPA was observed.
The total 12C BPA signal was the sum of unconjugated 12C BPA plus
12C BPA originating from conjugated metabolites after enzymatic
hydrolysis in pooled blank urine. Fig. 2B shows a representative
mass chromatogram obtained from the analysis of pooled urine
spiked with 12C BPA-G and 13C12-BPA-G at 0.5 ng/ml.The validation results are presented in Table 6. The 13C12-BPA
signal in water and human urine was zero. For 13C12-BPA-
G/13C12-BPA, the accuracy was 79–85%. The mean total 12C BPA
concentration in pooled blank urine was  0.379 ng/ml (n = 5). The
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Fig. 1. (A) Mass chromatogram of blank solvent (acetonitrile/water, 50/50) spiked with internal standard (BPA-d8, lower trace). No 12C BPA (upper trace, low signal, retention
time  4.97 min) and 13C12-BPA (middle trace, no signal) were added to the solvent. (B) Mass chromatogram of a calibration standard acetonitrile/water (50/50) spiked with
12C BPA (upper trace), 13C12-BPA (middle trace) and BPA-d8 (lower trace). The 12C BPA and 13C12-BPA concentration was  0.05 ng/ml.
Table 5
Validation results of total bisphenol A in pooled human urine. Pooled human urine was spiked with 12C-BPA and 13C12-BPA at six concentration levels. Each level was
pre-treated (SPE and -glucuronidase treatment). The mean total 12C-BPA concentration in pooled blank urine was 0.843 ng/ml (CV: 12.4%; n = 5).
Spiked Mean CV Correcteda Accuracy Mean accuracy
12C-BPA n = 5 12C-BPA conc. (%) 12C-BPA conc. 12C-BPA (%) 12C-BPA (%)
(ng/ml) (ng/ml) (ng/ml)
0.0 0.843 12.4 NA NA NA
0.20  1.0 2.0 0.16 71–93 78
0.50  1.3 3.5 0.51 88–109 101b
1.0 1.8 1.6 0.94 89–96 94
2.0  2.8 3.9 2.0 90–103 100
5.0  5.9 1.6 5.0 97–102 100
10.0  11.0 1.2 10.2 99–103 102
Spiked Mean CV Accuracy Mean accuracy
13C-BPA n = 5 13C-BPA conc. (%) 13C-BPA (%) 13C-BPA (%)
(ng/ml) (ng/ml)
0 0 NA NA NA
0.2  0.18 12.8 77–107 89
0.5  0.49 3.6 94–103 99
1  0.96 1.4 95–98 96
2  2 3.7 92–101 98
5  5 0.8 98–100 99
10  10.1 1.6 98–103 101
a The accuracy of 12C-BPA in spiked urine samples was calculated after subtraction of the mean signal in blank urine.
b One outlier (807%) excluded from average.
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Fig. 2. (A) Mass chromatogram of pooled blank human urine with internal standard (BPA-d8; lower trace) pre-treated with glucuronidase and SPE. The urine was not spiked
with 12C BPA (upper trace, retention time 4.96 min) and 13C12-BPA (middle trace). (B) Mass chromatogram of pooled human urine spiked with 12C BPA-glucuronide (0.5 ng/ml),
13C12-BPA-glucuronide (0.5 ng/ml) and internal standard (BPA-d8; lower trace). The 12C BPA-glucuronide and 13C12-BPA-glucuronide were enzymatically converted to 12C
BPA  (upper trace, retention time 4.97 min) and 13C12-BPA (middle trace, retention time 4.97 min).
Table 6
Validation results of total BPA in pooled human urine. Pooled human urine was  spiked with 12C-BPA-glucuronide and 13C12-BPA-glucuronide at six concentration levels. Each
level  was  pre-treated (SPE and glucuronidase treatment) and analyzed in 5-fold. The mean 12C-BPA concentration in pooled blank urine was 0.379 ng/ml (CV: 4.4%; n = 5).
Spiked Expected Mean CV Correcteda Accuracy Mean accuracy
12C-BPA-gluc n = 5 12C-BPA conc. 12C-BPA conc. (%) 12C-BPA conc. 12C-BPA (%) 12C-BPA (%)
(ng/ml)  (ng/ml) (ng/ml) (ng/ml)
0.0 0.0 0.379 4.4 NA NA NA
0.42  0.24 0.57 4.9 0.19 66–96 78
0.85  0.48 0.76 1.1 0.38 76–81 79
1.7  1.0 1.1 1.8 0.76 77–83 80
4.2  2.4 2.3 1.9 1.9 77–81 79
8.5  4.8 4.2 0.6 3.8 79–81 80
17.0  9.6 7.9 2.9 7.5 76–81 78
Spiked Expected Mean CV Accuracy Mean accuracy
13C-BPA-gluc n = 5 13C-BPA conc 13C-BPA conc. (%) 13C-BPA (%) 13C-BPA (%)
(ng/ml)  (ng/ml) (ng/ml)
0 0 0 NA NA NA
0.5  0.27 0.22 15.6 58–89 79
0.99  0.55 0.45 2.6 79–85 83
2  1.1 0.93 2.9 81–87 85
5  2.7 2.3 1.6 82–85 83
9.9  5.5 4.6 1.5 82–85 84
19.9  11 9 1.4 81–84 82
a The accuracy of 12C-BPA in spiked urine samples was calculated after subtraction of the mean signal in blank urine. The expected BPA concentration was calculated based
on  the molecular weight of BPA glucuronide and BPA as well as the purity.
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Table  7
Free 12C-BPA and total 12C-BPA concentrations in urine of 20 volunteers (sample
code V1–V20). The mean 12C-BPA concentration of each volunteer was  calculated
from three replicates. To monitor background 12C-BPA levels, blank water was  pre-
treated and analyzed in each run. The reported free and total 12C-BPA concentrations
were not corrected for background.
Sample Mean free CV Mean total CV
12C-BPA
concentration
(ng/ml; n = 3)
(%) 12C-BPA
concentration
(ng/ml; n = 3)
(%)
Water 0.097 24.6 0.108a 82.4a
V1 0.046 13.4 1.740 2.4
V2  0.054 12.9 1.082 5.3
V3  0.051 11.7 4.930 8.9
V4  0.051 21.7 0.243 13.2
V5  0.051 14.5 1.564 5.2
V6  0.119 19.8 6.812 5.1
V7 0.119 7.7 0.663 2.8
V8  0.037 21.6 0.247 10.5
V9  0.069 12.2 6.678 8.0
V10  0.035 20.5 0.553 28.8
V11  0.057 13.5 4.172 3.9
V12  0.040 24.2 1.064 1.7
V13  0.036 23.4 0.409 20.3
V14  0.038 15.1 0.664 10.1
V15  0.041 25.3 1.064 2.0
V16 0.039 24.7 0.975 1.4
V17  0.075 22.3 2.930 4.9
V18  0.069 4.6 0.677 8.9
V19  0.072 21.5 0.660 12.9
a
a
w
u
c
B
t
3
s
u
u
B
u
s
s
1
(
s
b
u
g
B
h
t
t
4
(
U
a
cV20  0.072 22.4 1.558 8.5
a The 12C-BPA concentration in blank water was 0.056, 0.065, 0.075, 0.078 ng/ml
nd 0.267 ng/ml.
ccuracy of 12C BPA from urine samples spiked with 12C BPA-G
as calculated after subtraction of the mean signal in pooled blank
rine. The accuracy of 12C BPA-G/12C-BPA was  78–80% at all con-
entration levels. The somewhat lower accuracy obtained for 12C
PA-G/12C-BPA may  have been caused by the hygroscopic nature of
he 12C BPA-G reference standard, used for spiking of pooled urine.
.5. Application of the methods to individual human urine
amples
The qualiﬁed methods were applied to urine samples of 20 vol-
nteers. All 20 urine samples were analyzed with both methods:
nconjugated 12C BPA was measured using SPE (n = 3), and total 12C
PA was measured using enzymatic treatment and SPE (n = 3). The
nconjugated and total BPA concentration of the individual urine
amples are presented in Table 7.
The unconjugated 12C BPA concentrations in the human urine
amples ranged from 0.035 ng/ml to 0.119 ng/ml. As the mean
2C BPA concentration in pre-treated (SPE) water was 0.097 ng/ml
n = 3) all mean 12C BPA concentrations measured in human urine
amples were at or below 0.097 ng/ml and can be considered
ackground. Only a few individual urine measurements showed
nconjugated 12C BPA concentrations at or just above the back-
round level and were also considered as background.
The mean total 12C BPA concentrations, i.e. unconjugated 12C
PA plus 12C BPA originating from conjugated metabolites, in the
uman urine samples varied from 0.243 ng/ml to 6.81 ng/ml. All
otal 12C BPA concentrations measured in the urine samples from
he 20 volunteers were above the background level.
. Conclusions
Trace-level quantitation of unconjugated and/or total 12C BPA
<1 ng/ml) in human urine and specimens is very challenging.
nconjugated BPA and total BPA should be measured in parallel and
 comprehensive trouble shooting analysis should be performed in
ases where substantial amounts (e.g., >1%) of unconjugated BPAr. B 1005 (2015) 30–38 37
are observed compared to total BPA [10,11]. Particular precautions
must be taken to avoid and to monitor contamination of BPA with
the appropriate blanks, controls and fortiﬁed controls during sam-
ple handling and analysis, since contamination might have a large
impact on BPA biomonitoring data [3,15–19,22].
As mentioned earlier by Markham et al. [20] the use of a surro-
gate analyte, in this case 13C BPA-G is strongly recommended as it
provides valuable information on method performance and aids in
method troubleshooting as it is not affected by exogenous 12C BPA.
During the study several pitfalls were encountered that resulted in
high BPA background levels. Comprehensive troubleshooting was
performed and precautions were taken to avoid and monitor 12C
BPA contamination (see Table 3A) including:
- Water used for all experiments was  extracted with
dichloromethane to eliminate trace amounts of BPA.
- All glass materials were pre-rinsed with dichloromethane to
eliminate trace amounts of BPA.
- A trap column was  installed between the mixing chamber and the
analytical column to separate BPA that originates from the UPLC
system from the BPA in the samples.
Even by taking the above mentioned precautions into account,
background contamination with BPA was  frequently in the range
of 0.01–0.02 ng/ml (solvent blank).
The method was  applied to urine samples from 20 volunteers.
Consistent with previously reported data in the literature, uncon-
jugated BPA concentrations are at or below the background level
and it can be concluded that no unconjugated BPA is present in any
human urine sample measured in this study.
Total BPA concentration in urine (0.243 ng/ml–6.81 ng/ml) is
consistent with earlier reports in large population studies conﬁrm-
ing low exposure to BPA in the general population [1,13,23–26].
Overall, the HPLC–MS/MS method developed by Markham et al.
[20] to determine unconjugated and total 12C BPA in urine was  suc-
cessfully transferred to another laboratory. Any analysis of BPA at
sub-ppb levels must strive to eliminate and continually monitor for
background contamination from all sources (collection to analysis)
with the appropriate blanks, controls and fortiﬁed controls.
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